Laird Norton Wetherby Wealth Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-56	Closed	-$48K	–	736
2020 Q2	$48K	Hold	56	–	–	﹤0.01%	709
2020 Q1	$35K	Hold	56	–	–	﹤0.01%	674
2019 Q4	$58K	Hold	56	–	–	0.01%	697
2019 Q3	$48K	Hold	56	–	–	0.01%	696
2019 Q2	$74K	Hold	56	–	–	0.01%	675
2019 Q1	$82K	Hold	56	–	–	0.01%	656
2018 Q4	$68K	Hold	56	–	–	0.01%	624
2018 Q3	$136K	Hold	56	–	–	0.02%	647
2018 Q2	$119K	Hold	56	–	–	0.02%	627
2018 Q1	$56K	Hold	56	–	–	0.01%	635
2017 Q4	$92K	Hold	56	–	–	0.01%	635
2017 Q3	$91K	Buy	+56	New	+$77.5K	0.01%	609

Other funds holding GLMD

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's GLMD Position: Q3 2020 in Review

Laird Norton Wetherby Wealth Management sold out of Galmed Pharmaceuticals (GLMD) in Q3 2020, closing a stake of 56 shares — an estimated $48K sold.

Laird Norton Wetherby Wealth Management first reported a position in GLMD in Q3 2017 and held it in 12 quarters. The position peaked at $136K in Q3 2018. 24 funds tracked by Wall St. Rank hold GLMD as of Q3 2020.

Laird Norton Wetherby Wealth Management reported no remaining Galmed Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Laird Norton Wetherby Wealth Management sold 56 Galmed Pharmaceuticals shares in Q3 2020, an estimated $48K.
Laird Norton Wetherby Wealth Management first reported a position in Galmed Pharmaceuticals in Q3 2017 and held it in 12 quarters.
Laird Norton Wetherby Wealth Management's Galmed Pharmaceuticals position peaked at $136K in Q3 2018.
24 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2020.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2020, filed 13 Nov 2020.